A drug that induces the microRNA miR-124 enables differentiation of retinoic acid–resistant neuroblastoma cells
- 15 April 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (882) , eads2641
Abstract
Tumor cell heterogeneity in neuroblastoma, a pediatric cancer arising from neural crest–derived progenitor cells, presents clinical challenges. Unlike adrenergic (ADRN) neuroblastoma cells, neuroblastoma cells with a mesenchymal (MES) identity are resistant to chemotherapy and retinoid therapy, which contributes to relapses and treatment failures. We explored whether up-regulation of the neurogenic, tumor suppressor microRNA miR-124 could promote the differentiation of retinoic acid–resistant MES neuroblastoma cells. Leveraging our screen for miRNA-modulatory small molecules, we identified and validated the tyrosine and phosphoinositide kinase inhibitor PP121 as a robust inducer of miR-124. Combining PP121 and BDNF-activating bufalin synergistically arrested proliferation and promoted the sustained differentiation of MES/heterogeneous SK-N-AS cells over several weeks. This protocol also resulted in the differentiation of multiple MES neuroblastoma and glioblastoma cell lines. RNA-seq analysis of differentiated MES/heterogeneous SK-N-AS cells revealed the replacement of the ADRN core regulatory circuitry with circuitries associated with chromaffin cells and Schwann cell precursors. Furthermore, differentiation was associated with inhibition of the CDK4/CDK6 pathway and activation of a transcriptional program that correlated with improved outcomes for patients with neuroblastoma. Our findings suggest an approach with translational potential to induce the differentiation of therapy-resistant cancers of the nervous system. Moreover, these long-lived, differentiated cells could be used to study mechanisms underlying cancer biology and therapies.Keywords
This publication has 67 references indexed in Scilit:
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- MicroRNA‐124: An emerging therapeutic target in cancerCancer Medicine, 2019
- microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human gliomaBiochemical and Biophysical Research Communications, 2018
- The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121Biochemical and Biophysical Research Communications, 2015
- miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4Tumor Biology, 2015
- PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migrationTumor Biology, 2014
- Cardiac Glycoside ToxicityCritical Care Clinics, 2012
- Retinoic acid induces REST degradation and neuronal differentiation by modulating the expression of SCFβ‐TRCP in neuroblastoma cellsCancer, 2011
- Biophysical Regulation of Histone Acetylation in Mesenchymal Stem CellsBiophysical Journal, 2011
- Bioactive principles in the bark of Pilidiostigma tropicumJournal of Molecular Modeling, 2006